Atorvastatin cuts anthracycline heart failure

Published Date: 08 Mar 2023

Atorvastatin 40 mg daily for 12 months reduces cardiovascular events in lymphoma patients treated with anthracyclines.

Read Full News

Latest News

Upadacitinib Switch from Dupilumab Effective in Head and Neck Atopic Dermatitis

Updated Urticaria Guidelines Clarify Diagnosis, Biomarkers, Treatment Pathways

6 Dermatology Headlines You Missed in January 2026

Bimekizumab Demonstrates Long Term Efficacy in Hidradenitis Suppurativa

Expert Consensus on Knowledge Gaps in Dermatology for Skin of Color, With Henry Lim, MD Henry Lim, MD

This interview with Lim highlights knowledge gaps examined by an international expert panel reviewing existing literature on dermatologic disease in skin of color.

Upadacitinib Regulatory Applications Submitted for Adults, Adolescents with Vitiligo

Todays Updates

Phase 3b RESHAPE Study Evaluates Risk–Benefit of Switching From Ocrelizumab to BTK Inhibitor Remibrutinib Isabella Ciccone, MPH

A phase 3b study presented at ACTRIMS 2026 is evaluating whether switching to remibrutinib offers efficacy and safety comparable to continued ocrelizumab treatment in relapsing multiple sclerosis.

Todays Updates

Phase 3b RESHAPE Study Evaluates Risk–Benefit of Switching From Ocrelizumab to BTK Inhibitor Remibrutinib Isabella Ciccone, MPH

A phase 3b study presented at ACTRIMS 2026 is evaluating whether switching to remibrutinib offers efficacy and safety comparable to continued ocrelizumab treatment in relapsing multiple sclerosis.

Latest News

Upadacitinib Switch from Dupilumab Effective in Head and Neck Atopic Dermatitis

Updated Urticaria Guidelines Clarify Diagnosis, Biomarkers, Treatment Pathways

6 Dermatology Headlines You Missed in January 2026

Bimekizumab Demonstrates Long Term Efficacy in Hidradenitis Suppurativa

This interview with Lim highlights knowledge gaps examined by an international expert panel reviewing existing literature on dermatologic disease in skin of color.

Upadacitinib Regulatory Applications Submitted for Adults, Adolescents with Vitiligo

News All Time

Practical Approaches to Hyperpigmentation and Hypopigmentation, With Nada Elbuluk, MD, MSc, and Michelle Rodrigues, MBBS Nada Elbuluk, MD, MSc, Michelle Rodrigues, MBBS

This segment of the latest Skin of Color Savvy episode highlights a conversation between Nada Elbuluk, MD, MSc, and Michelle Rodrigues, MBBS.

Skin of Color Savvy: Highlights from 2025 Tim Smith

In this end-of-year reel, HCPLive has showcased several key highlights from the Skin of Color Savvy podcast in 2025.

Skin of Color Savvy: On-Site Interviews at the Meeting the Challenge Summit Angel S. Byrd, MD, PhD, Valerie D. Callender, MD, Valerie Harvey, MD, MPH, Stafford Brown, MD, MBA

This episode of Skin of Color Savvy was filmed on-site at the Skin of Color Society's 'Meeting the Challenge Summit' in Washington, DC.

Skin of Color Savvy: Highlights From the Most-Watched Episodes of 2025 Andrew F Alexis, MD, MPH, Shawn Kwatra, MD, Crystal Aguh, MD, FAAD, John E. Harris, MD, PhD, Nada Elbuluk, MD, MSc, Michelle Rodrigues, MBBS

This new episode from January 2026 features a compilation of 3 clips from the most viewed episodes of 2025.

Maui Derm 2026 Presentation Highlights Icotrokinra, Other New Dermatology Drugs

The HCPFive: Top News for Healthcare Providers from the Week of 01/18

Amlitelimab Effective, Safe for Atopic Dermatitis in Patients 12 Years and Older

LEVEL UP: New Data on Switching from Dupilumab to Upadacitinib in Atopic Dermatitis

Personalized Care Improvements Identified for Older Patients with Skin Cancer

What to Expect at the 2026 Maui Derm Conference

New Findings on Acne Incidence in Transgender Individuals, With Howa Yeung, MD, MSc

Topical Antioxidant Serum May Be Effective in Treating Atrophic Acne Scars

Melanoma Surgery Delay After 4 Weeks Post-Diagnosis Decreases Survival Rates

Ritlecitinib Efficacious for Non-Segmental Vitiligo Across Various Subgroups

ICP-332 Effective, Safe for Treating Moderate to Severe Atopic Dermatitis

Unmet Needs Highlighted Regarding CSU Treatment Escalation

In early dementia, SSRIs enhance cognition and major depression.

How wildfires pose challenges to cancer care

Participate and win cash vouchers

Get updates on the latest events happening around the world

2.

Unlocking the potential of targeted therapies for multiple myeloma

3.

Researchers Challenge USPSTF's Lung Cancer Screening Criteria

4.

Q&A: Odds of surviving cancer drop drastically when credit score dips

5.

Children with rare gliomas have new hope thanks to clinical trial results.

1.

Understanding the HAS-BLED Score: What It Is and Why It Matters

2.

Pembrolizumab Plus Lenvatinib in EBV-Associated Advanced Intrahepatic Cholangiocarcinoma: Case Study

3.

Antibody-Drug Conjugates and the Dawn of Targeted Cancer Therapy in 2025

4.

A Comprehensive Guide to Carcinoma in Situ: Types, Risks, and Preventive Measures

5.

Revolutionizing Cancer Treatment: The Promise of Bevacizumab Injections

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Navigating the Complexities of Ph Negative ALL - Part XIII

2.

Navigating the Complexities of Ph Negative ALL - Part II

3.

Should We Use DARA Up Front As First-Line Therapy in MM?

4.

Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part III

5.

Incidence of Lung Cancer- An Overview to Understand ALK Rearranged NSCLC

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug Database Drug Interaction Diseases Database

KOL Videos Knowledge Hub Quizzes

Medical Updates Events About Us

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation

Atorvastatin cuts anthracycline heart failure

Latest News

Upadacitinib Switch from Dupilumab Effective in Head and Neck Atopic Dermatitis

Updated Urticaria Guidelines Clarify Diagnosis, Biomarkers, Treatment Pathways

6 Dermatology Headlines You Missed in January 2026

Bimekizumab Demonstrates Long Term Efficacy in Hidradenitis Suppurativa

Expert Consensus on Knowledge Gaps in Dermatology for Skin of Color, With Henry Lim, MD Henry Lim, MD

Upadacitinib Regulatory Applications Submitted for Adults, Adolescents with Vitiligo

Todays Updates

Phase 3b RESHAPE Study Evaluates Risk–Benefit of Switching From Ocrelizumab to BTK Inhibitor Remibrutinib Isabella Ciccone, MPH

Todays Updates

Phase 3b RESHAPE Study Evaluates Risk–Benefit of Switching From Ocrelizumab to BTK Inhibitor Remibrutinib Isabella Ciccone, MPH

Latest News

News All Time

Practical Approaches to Hyperpigmentation and Hypopigmentation, With Nada Elbuluk, MD, MSc, and Michelle Rodrigues, MBBS Nada Elbuluk, MD, MSc, Michelle Rodrigues, MBBS

Skin of Color Savvy: Highlights from 2025 Tim Smith

Skin of Color Savvy: On-Site Interviews at the Meeting the Challenge Summit Angel S. Byrd, MD, PhD, Valerie D. Callender, MD, Valerie Harvey, MD, MPH, Stafford Brown, MD, MBA

Skin of Color Savvy: Highlights From the Most-Watched Episodes of 2025 Andrew F Alexis, MD, MPH, Shawn Kwatra, MD, Crystal Aguh, MD, FAAD, John E. Harris, MD, PhD, Nada Elbuluk, MD, MSc, Michelle Rodrigues, MBBS

Maui Derm 2026 Presentation Highlights Icotrokinra, Other New Dermatology Drugs

The HCPFive: Top News for Healthcare Providers from the Week of 01/18

Amlitelimab Effective, Safe for Atopic Dermatitis in Patients 12 Years and Older

LEVEL UP: New Data on Switching from Dupilumab to Upadacitinib in Atopic Dermatitis

Personalized Care Improvements Identified for Older Patients with Skin Cancer

What to Expect at the 2026 Maui Derm Conference

New Findings on Acne Incidence in Transgender Individuals, With Howa Yeung, MD, MSc

Topical Antioxidant Serum May Be Effective in Treating Atrophic Acne Scars

Melanoma Surgery Delay After 4 Weeks Post-Diagnosis Decreases Survival Rates

Ritlecitinib Efficacious for Non-Segmental Vitiligo Across Various Subgroups

ICP-332 Effective, Safe for Treating Moderate to Severe Atopic Dermatitis

Unmet Needs Highlighted Regarding CSU Treatment Escalation

Recommended News For You

A new theranostic drug targets different cancer types.

ALK Inhibitor Shows Promise in Rare, Progressive Tumor Types

According to JAMA, statin use may increase cancer-related survival in breast cancer patients.

Hit and Miss for CDK4/6 Inhibitor in Recurrent Brain Cancer

Breast density changes over time are associated with an increased risk of cancer.

In early dementia, SSRIs enhance cognition and major depression.

How wildfires pose challenges to cancer care

Recommended Articles For You

CAR-T Cell Therapy for B-Cell Acute Lymphoblastic Leukemia: A Comprehensive Review

Revolutionizing Cancer Treatment: How Adoptive Cell Therapy is Overcoming Tumor Immune Evasion

Precision Medicine and Genomics: Revolutionizing Healthcare Through Personalized Treatment

Bridging Heart and Cancer Care: The Essential Framework of a Modern Cardio-Oncology Program

Whats more on Hidoc Dr.

Medical Updates

KOL Videos

Surveys

Events

Featured News

Featured Articles

Featured Events

Featured KOL Videos

Quick Links

Verification

Welcome to Hidoc Dr.